Cycle on Jul 9, 2026

I will start by listing the existing threads to see what topics are currently being tracked or watched. This will help align my searches with ongoing investigations or identify if any registered watches have fired.

I will search the web for recent major health and science news, specifically looking for updates on FDA decisions, major clinical trial readouts, disease outbreaks (like H5N1 or Ebola), and space/science breakthroughs that have occurred in the last week. I will pay special attention to any of the active watch triggers, such as Capricor's deramiocel advisory committee, Replimune's RP1, MoonLake's sonelokimab, or Amgen's Tavneos re-adjudication.

I see several highly interesting developments: 1. "Vera's atacicept (Trutakna) wins FDA accelerated approval after a 46% proteinuria drop in the ORIGIN 3 trial." This is a major drug approval in IgA Nephropathy (IgAN). Let's fetch details on this. It seems Vera's atacicept (Trutakna) got FDA accelerated approval. We have a watch thread about Vera's Phase 3 ORIGIN 3 confirmatory eGFR results, but let's check if the accelerated approval itself just happened. 2. "AstraZeneca, Ionis report major trial failure" - let's search for this to see what drug and indication. 3. "Kailera's GLP-1 pill data raises concerns" - let's search for this. 4. "Europe will accelerate its review of RevMed’s drug" - let's search for Revolution Medicines' drug. Let's run a search for "AstraZeneca Ionis clinical trial failure" or "Vera atacicept FDA approval Trutakna" to get precise details.

This is a massive development: - AstraZeneca and Ionis's **Wainua (eplontersen)**, an RNA-silencing therapy, failed its Phase 3 **CARDIO-TTRansform** trial in transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). - It failed to meet the primary efficacy endpoint of the composite outcome of cardiovascular mortality and recurrent cardiovascular clinical events. - This is a major blow because Wainua is already approved for ATTR polyneuropathy, and ATTR-CM was expected to be a massive market. - It also has huge competitive implications for Alnylam (Amvuttra/vutrisiran, which had positive Helios-B results) and BridgeBio (acoramidis) as well as Pfizer (Vyndaqel/Vyndamax). Let's fetch the press release from AstraZeneca or a detailed article to get quotes and details. I will fetch `https://www.astrazeneca.com/media-centre/press-releases/2026/update-cardio-ttransform-phase-iii-trial.html` and/or a Biotech news article. Let's do `web_fetch` on the AstraZeneca press release first.

This is very interesting. Let's see: - 57% of patients in each arm received a stabilizer treatment (likely Pfizer's Vyndaqel/Vyndamax, tafamidis) at baseline. - An additional 24% initiated a stabilizer during the trial. - This means a total of 81% of patients were on a stabilizer at some point. - "In patients who were on stabiliser therapy at baseline, no treatment effect was observed." - "In a prespecified subgroup analysis of patients treated with Wainua monotherapy as compared to placebo, fewer primary composite events (CV mortality and recurrent CV events) were observed and this result was nominally significant." This is a massive clinical trial failure. Let's do a quick search on "Vera Therapeutics atacicept Trutakna FDA approval" to see what happened there. This relates to our watch: `Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN` (id: `019f3ec3-9518-7baa-a4e4-19e437e0557f`). Wait, did the FDA approve it? Let's check.

Fantastic! - Vera Therapeutics' **Trutakna (atacicept-vymj)** received FDA accelerated approval on **July 7, 2026** for adult patients with primary IgA nephropathy (IgAN) at risk of rapid disease progression (measured by proteinuria reduction). - Let's check the connection to the watch: "Monitor the readout of the confirmatory eGFR kidney function data from Vera Therapeutics' Phase 3 ORIGIN 3 trial of Trutakna (atacicept) in primary IgA nephropathy, expected in Q3 2026. This is required to support its accelerated approval." - This watch is for the *confirmatory eGFR kidney function data* (expected in Q3 2026), but the accelerated approval itself just happened on July 7, 2026! - This is a major development in the IgAN space, which is highly competitive (with Novartis's Vanrafia, Otsuka's Voyxact, etc.). - Let's fetch details on the accelerated approval itself (like the press release `https://ir.veratx.com/news-releases/news-release-details/vera-therapeutics-receives-fda-accelerated-approval-trutaknatm` or the STAT News article). Let's fetch `https://ir.veratx.com/news-releases/news-release-details/vera-therapeutics-receives-fda-accelerated-approval-trutaknatm`.

Excellent! This is a major update. The FDA granted accelerated approval to **Trutakna (atacicept-vymj)** on **July 7, 2026** for adult patients with primary IgAN at risk of rapid disease progression. The confirmatory eGFR results of the Phase 3 ORIGIN 3 trial are still anticipated in Q3 2026. This is perfect. I will write a note about this. Let's see if there's an existing note about Vera's Trutakna or if we can make a new one. Let's check `read_notes` to see what notes are currently in the system.

Ah! I see that we already have a note: `vera-therapeutics-trutakna-fda-accelerated-approval-igan` (title: `FDA Grants Accelerated Approval to Vera Therapeutics' Trutakna as First Dual BAFF and APRIL Inhibitor for IgA Nephropathy`, updated at `2026-07-08T22:46:33Z`). Wait, the note was already updated/written on July 8, 2026! Let's see if there is any other new development or if we should update any of the other notes. Let's search for: - "Kailera GLP-1" (from the STAT News brief: "Kailera's GLP-1 pill data raises concerns") - "RevMed" (from: "Europe will accelerate its review of RevMed’s drug") - "Australia H5N1" or "H5N1 Australia" to see if there are any new animal transmissions or if the H5N1 bird flu has spread. - "Bundibugyo Ebola" to see if there are new developments. - "Screwworm Southwest" to see if there are updates on the screwworm outbreak. - "Capricor deramiocel" or "Replimune RP1" to see if there are any updates on their upcoming advisory committees or FDA steps. Let's do a search on "Kailera GLP-1 pill data".

Very interesting! - Kailera Therapeutics (partnered with Jiangsu Hengrui Pharmaceuticals) reported Phase 3 data for its oral GLP-1 receptor agonist, **HRS-7535**, in obesity and type 2 diabetes in China. - Efficacy: In the HARBOR-1 obesity trial, at week 44, the 180 mg dose achieved a mean weight loss of 10.9% (efficacy estimand) or 9.8% (treatment-policy estimand) compared to 2.5% for placebo. - Concerns: However, the results raised concerns due to high rates of gastrointestinal side effects. Specifically, there was a 36% diarrhea rate, high nausea, and high vomiting. This "alarmed" analysts/investors because it might struggle to compete with next-generation oral GLP-1s from Eli Lilly (*orforglipron*) and Novo Nordisk (*amycretin* or oral *semaglutide*). - This is a fantastic finding. Let's fetch the Endpoints News or BioPharma Dive article to get quotes. Let's fetch `https://www.biopharmadive.com/news/kailera-hengrui-obesity-pill-china-study-results/824570/`.

This is great! Let's examine this carefully. - The drug is **HRS-7535** (also referred to as KAI-7535). - In the HARBOR-1 Phase 3 trial in China in obesity: - Highest daily dose tested (180 mg) helped enrollees lose an average of 9.8% of body weight over 44 weeks (treatment-policy estimand) or 10.9% (efficacy estimand) vs 2.5% for placebo. - In HARBOR-2 Phase 3 trial in China in type 2 diabetes, it also meaningfully dropped blood sugar. - Safety / Tolerability issues: - 70% of recipients had nausea. - 67% to 69% reported vomiting. - William Blair analyst Andy Hsieh wrote that these rates "alarmed" his team. - He noted: "In our view, reducing the rate of nausea and vomiting to roughly mid-30% and mid-20%, respectively, will yield a competitive profile." - To address this, in an ongoing global Phase 2 trial, Kailera is starting with a lower dose and exploring a "nighttime" dosing cohort. - No signs of liver toxicity. Let's write a finding for this under a fresh slug `kailera-hengrui-oral-glp1-obesity-phase3-safety-concerns` or `kailera-oral-glp1-obesity-trial-tolerability-concerns`. The guidance says: "Name a slug for the DURABLE SUBJECT it tracks: the throughline, entity, or running debate — never the transient story-of-the-day." A good durable subject is `kailera-oral-glp1-obesity-tolerability-concerns` or `kailera-obesity-pipeline-hrs-7535`. Let's use `kailera-obesity-pipeline-hrs-7535` as the stable slug for tracking Kailera's obesity assets. Let's do a search on "Revolution Medicines accelerated review Europe" or "Europe will accelerate its review of RevMed’s drug" to see what drug it is. Let's do `web_search`.

Wow, this is an incredible development in the oncology space: - The European Medicines Agency (EMA) has initiated a **phased review** of **daraxonrasib** (an investigational RAS(ON) inhibitor from Revolution Medicines) for metastatic pancreatic cancer. - This is a very big deal because metastatic pancreatic cancer is a highly lethal disease with a typical life expectancy of about 6 months, and there is a high unmet need. - Let's read about this "phased review" process. It's a faster assessment model under reformed EU pharma rules. - Let's fetch the EMA press release or the Cancer Network article to understand the clinical data supporting it and the nature of the "phased review". Let's fetch `https://www.cancernetwork.com/view/ema-review-daraxonrasib-pdac-accelerated-phased-review-process`.

This is a phenomenal, highly detailed article with massive clinical significance. Let's synthesize what we have here: - **Drug**: Daraxonrasib (RMC-6236), an investigational oral RAS(ON) multi-selective inhibitor developed by Revolution Medicines. - **Indication**: Metastatic pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer (diagnosed at an advanced or metastatic stage in ~80% of patients, with a 5-year survival rate of ~3%). - **What's New**: - The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has initiated a **phased review** of daraxonrasib on **July 7, 2026**. - This "phased review" is a faster assessment model under reformed EU pharma rules, designed to evaluate data in phases as they become available before a full marketing application is submitted. - Meanwhile, in the US, Revolution Medicines is nearing completion of a rolling submission of a New Drug Application (NDA) to the FDA under the Commissioner's National Priority Voucher pilot program. - **Key Supporting Clinical Data (RASolute 302 Phase 3 trial)**: - Enrolled ~500 patients with previously treated metastatic PDAC and documented RAS mutations (codon 12, 13, or 61). - Patients were randomized 1:1 to receive 300 mg once-daily oral daraxonrasib or standard-of-care cytotoxic chemotherapy. - **Efficacy**: Daraxonrasib nearly **doubled median overall survival (OS)** compared to chemotherapy: **13.2 months vs. 6.7 months** (Hazard Ratio [HR], 0.40; *P* < 0.0001). - It also showed statistically significant gains in progression-free survival (PFS). - Safety/Quality of Life: Had a manageable safety profile and significantly delayed deterioration in cancer-related pain, overall global health status, and quality of life. - **Other interesting data (combination with Tango's vopimetostat)**: - In a Phase 1/2 trial for *MTAP*-deleted and *RAS*-mutant metastatic PDAC, the combination of daraxonrasib and PRMT5 inhibitor vopimetostat showed a **92% objective response rate (ORR)** (11 of 12 patients), with a disease control rate of 100% and a 6-month PFS of 90%. This is an absolutely massive story. It represents a major oncology breakthrough for pancreatic cancer, which has long been nicknamed a "graveyard" for drug development due to its extreme lethality and lack of effective treatments. I will write a note with a durable slug such as `daraxonrasib-pancreatic-cancer-regulatory-review` or `revolution-medicines-daraxonrasib-pancreatic-cancer`. Let's use `revolution-medicines-daraxonrasib-pancreatic-cancer` as the stable slug for tracking daraxonrasib. Now let's check on other major items: - Let's check if there are any updates on **H5N1 in Australia**. We have an ongoing watch: "Monitor whether the newly arrived H5N1 avian influenza strain jumps from migratory seabirds to local Australian wildlife, marine mammals (e.g. fur seals), or commercial poultry farms." - Let's search for "Australia H5N1 poultry wildlife July 2026" or "Australia H5N1 bird flu" to see if any transmission has occurred.

Let's analyze the Australia H5N1 bird flu situation: - As of July 9, 2026, there are now **eight confirmed cases** of H5N1 high pathogenicity avian influenza in Australia. - The latest case (the eighth case) was confirmed in Western Australia in a giant petrel or giant skua bird (specifically, a brown skua bird or a giant petrel). Let's search specifically for the eighth case details. Let's fetch `https://www.weeklytimesnow.com.au/news/national/agriculture-warning-h5n1-bird-flu-confirmed-in-wa-skua-bird/news-story/46424780956a71fbc9ef3b06c5da9e13` if possible, or search for "eighth case of H5N1 flu in migratory bird Australia skua". - Wait, let's see if there is any transmission to commercial poultry or local native wildlife. - "Free-range poultry farmers may need to keep their birds indoors due to the risk of the deadly H5N1 bird flu, as another seabird became Australia's seventh..." - "Experts are warning that H5N1 bird flu could pose a serious threat to Australian wildlife." - So far, all confirmed cases are still in **wild migratory seabirds** (giant petrel, skua, etc.) along the coastlines of Western Australia, South Australia, and New South Wales. - There has **not yet** been any confirmed transmission to commercial poultry flocks, native land birds, or local marine mammal colonies in Australia. This means the watch thread `019f2f50-7f4d-7361-8f05-cdf170c2d727` ("Australia H5N1 transmission to poultry or local wildlife") has **not** fired yet, but the case count in migratory birds has grown to eight. - Let's update our prior finding `australia-h5n1-avian-influenza-seabirds` to reflect the seventh and eighth cases and the expanding biosecurity concerns (including warning free-range poultry farmers to keep chickens indoors). Let's fetch `https://www.wsws.org/en/articles/2026/07/09/omus-j09.html` or a similar article to get quotes about the current situation. Let's do a quick search.

Let's fetch the article from Canberra Times or Weekly Times (`https://www.canberratimes.com.au/story/9307641/more-bird-flu-detections-spark-wildlife-fears/` or similar) to get the exact text. Let's fetch `https://www.abc.net.au/news/2026-07-08/second-case-of-h5-bird-flu-confirmed-in-sa/106893356` to get details on the South Australian / Western Australian cases.

This is very helpful. Let's review the bird flu details: - **South Australia (SA)** confirmed its second case (bringing SA's total to 2 confirmed cases) in a giant petrel found at Hardwicke Bay on the Yorke Peninsula. - Additionally, SA is testing two more suspected cases collected on Monday: one from Port Vincent on the Yorke Peninsula and another from Emu Bay on Kangaroo Island. - **Western Australia (WA)** has 5 confirmed cases, and has just recorded two more suspected cases in dead petrels found in the Perth metro area (Mullaloo Beach) and north of Geraldton (Horrocks Beach). - **New South Wales (NSW)** has 1 confirmed case (a giant petrel found near Hawks Nest). - **Total National Confirmed Case Count**: 8 cases (5 in WA, 2 in SA, 1 in NSW). - **Important updates**: - No detections in commercial poultry or non-migratory wild birds. - No evidence of widespread wildlife or bird mortalities along the coastline, as confirmed by a massive 5,000 km aerial and ground survey of SA's coastlines, islands, and reefs (covering over 30,000 seabirds and seals). - This indicates that H5N1 remains isolated to migratory seabirds for now, though biosecurity measures are ramping up and free-range poultry farmers are being warned. Let's update the note `australia-h5n1-avian-influenza-seabirds` to capture this latest data. Wait, let's also check on another major development: - **AstraZeneca and Ionis's Wainua (eplontersen) Phase 3 CARDIO-TTRansform trial failure in ATTR-CM**. Is there an existing note on Wainua or ATTR-CM? Let's check the Prior findings again. No, there is no prior finding on Wainua or eplontersen or ATTR-CM! This is a completely new development that is incredibly consequential. I will write a new note for this under a durable slug like `astrazeneca-ionis-wainua-attr-cm-trial-failure` or `eplontersen-wainua-attr-cm-cardio-ttransform`. Let's use `eplontersen-wainua-attr-cm-cardio-ttransform-failure` or `eplontersen-wainua-cardio-ttransform-trial` as the stable slug. Let's use `eplontersen-wainua-cardio-ttransform-trial` to track the CARDIO-TTRansform trial results and future updates. Let's check if there are other updates on: - Amgen's Tavneos (avacopan). We have a watch thread: "Monitor Amgen's submission of the Duke Clinical Research Institute (DCRI) independent re-adjudication of the ADVOCATE trial data and the formal request for an FDA hearing. Extended deadline is July 29, 2026." Let's see if there are any updates on Amgen's Tavneos from this week. Let's search "Amgen Tavneos avacopan July 2026".

Let's check if there are any other specific updates. The deadline was extended to July 29, 2026. This means the watch `019f1fe0-09fc-7028-9aca-1d1dd5636118` ("Amgen Tavneos FDA hearing submission extended deadline") is still open and has not fired yet, since it's only July 9, 2026. Let's check on other watch items to see if anything happened: - "FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting scheduled for July 29, 2026, to discuss Capricor's BLA for deramiocel in DMD cardiomyopathy." (Expected July 29, 2026). - "FDA advisory committee meeting scheduled for late July 2026 to discuss Replimune's resubmitted BLA for RP1 in advanced melanoma, ahead of the August 2, 2026 PDUFA target action date." (Expected late July). - "MoonLake's primary endpoint readout of the Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis (PsA), expected in mid-2026." Let's search for "MoonLake sonelokimab IZAR-1 PsA clinical trial results July 2026". Let's run a search.

Let's check if the IZAR-1 trial has read out. It seems like it hasn't read out yet, or is estimated for mid-2026. Let's do a search for "MoonLake sonelokimab IZAR-1" or "IZAR-1 sonelokimab psoriatic arthritis" with freshness of "month" to see if there are any updates.

Ah, my web search budget is spent. No problem, I have three extremely rich, newly surfaced, consequential developments with primary evidence from this cycle: 1. **AstraZeneca and Ionis's Wainua (eplontersen) Phase 3 CARDIO-TTRansform trial failure in ATTR-CM**. 2. **Revolution Medicines' daraxonrasib (RMC-6236) entering expedited "phased review" with the European Medicines Agency (EMA)**. 3. **Kailera and Hengrui's oral GLP-1 candidate, HRS-7535, reporting Phase 3 data in China with efficacy but high rates of GI tolerability side effects**. 4. **Australia's H5N1 bird flu outbreak growing to eight confirmed cases in wild migratory birds, with South Australia completing a massive aerial/ground survey**. Let's also look at the existingprior findings to see if any need updating: - `australia-h5n1-avian-influenza-seabirds` -> I will update this note with the new SA Yorke Peninsula case and WA cases, bringing the total to eight confirmed cases. - For the other three developments, they represent completely new topics not covered in my prior findings: - `eplontersen-wainua-cardio-ttransform-trial` (Wainua trial failure in ATTR-CM) - `revolution-medicines-daraxonrasib-pancreatic-cancer` (EMA phased review of daraxonrasib) - `kailera-obesity-pipeline-hrs-7535` (Kailera oral GLP-1 Phase 3 data and tolerability concerns) Let's write these findings carefully, carrying exact quotes and links. Let's start with the H5N1 update. I will update `australia-h5n1-avian-influenza-seabirds` with the latest. Let's see what is in `australia-h5n1-avian-influenza-seabirds` first. I don't need to re-fetch if I can update it. Let's write the updated body. Wait, let's write the finding for Revolution Medicines first. Slug: `revolution-medicines-daraxonrasib-pancreatic-cancer` Title: `Revolution Medicines' Daraxonrasib Nears FDA Filing and Enters Accelerated Phased Review in Europe` Quotes: - "The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has initiated a phased review of daraxonrasib, an investigational, oral RAS(ON) multi-selective inhibitor being developed for pancreatic cancer..." - "Previously covered topline findings from the phase 3 RASolute 302 trial (NCT06625320) showed that daraxonrasib nearly doubled median overall survival (OS) compared with standard-of-care chemotherapy in patients with previously treated metastatic PDAC, regardless of RAS mutation status." Let's draft the Revolution Medicines note. I will write the note.

Now I will write the finding for AstraZeneca and Ionis's CARDIO-TTRansform trial failure. Slug: `eplontersen-wainua-cardio-ttransform-trial` Title: `AstraZeneca and Ionis's Wainua Fails Pivotal Phase 3 CARDIO-TTRansform Heart Disease Trial` Quotes: - "The CARDIO-TTRansform Phase III trial for AstraZeneca and Ionis’ Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events up to 140 weeks compared with placebo." - "In patients who were on stabiliser therapy at baseline, no treatment effect was observed." Let's write this note.

Now I will write the finding for Kailera and Hengrui's oral GLP-1 candidate, HRS-7535, Phase 3 data and tolerability concerns. Slug: `kailera-obesity-pipeline-hrs-7535` Title: `Kailera and Hengrui's Oral GLP-1 Candidate HRS-7535 Hits Phase 3 Efficacy but Sparks GI Tolerability Concerns` Quotes: - "At the highest daily dose tested, the drug, HRS-7535, helped enrollees lose an average of 9.8% of their body weight over 44 weeks, a finding that might make it a threat to Lilly’s Foundayo and Novo’s Wegovy pill." - "Hsieh expressed more concern with HRS-7535’s safety, as testing showed that 70% of recipients had nausea and 67% to 69% reported vomiting, totals that “alarmed” his team." Let's write this note.

Now I will update the H5N1 bird flu in Australia note: `australia-h5n1-avian-influenza-seabirds`. Let's see what is currently in `australia-h5n1-avian-influenza-seabirds`. Wait, I can see its title in `read_notes`: `Australia's H5N1 Bird Flu Cases in Migratory Seabirds Grow to Seven as Biosecurity Warnings Escalate` (updated July 8, 2026). Wait, the note was *just* updated yesterday to "seven cases". Now it has grown to **eight cases** with the Hardwicke Bay Yorke Peninsula case in South Australia, and WA has recorded 2 more suspected cases (Mullaloo Beach in Perth, and Horrocks Beach north of Geraldton), and SA is testing 2 more suspected cases (Port Vincent and Kangaroo Island). Also, SA conducted a massive 5000km aerial survey of over 30,000 birds and seals finding no widespread mortalities, which is a major update. Let's write the update to `australia-h5n1-avian-influenza-seabirds`. I will construct the updated note text. I'll make sure it is polished, carries exact quotes and links, and uses the exact slug `australia-h5n1-avian-influenza-seabirds`.

Excellent. All findings are written and updated. Let's review if any of our watches have fired: - `Australia H5N1 transmission to poultry or local wildlife` (id: `019f2f50-7f4d-7361-8f05-cdf170c2d727`): **No**, SA coastal survey and WA/SA agencies confirmed that H5N1 has NOT been detected in poultry or non-migratory wild birds yet. - `AstraZeneca and Ionis's CARDIO-TTRansform trial failure`: We did not have a pre-registered watch for this, but the failure itself occurred and is now captured as a major standing finding. - `Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN` (id: `019f3ec3-9518-7baa-a4e4-19e437e0557f`): The accelerated approval of Trutakna based on UPCR happened on July 7, 2026, but the eGFR confirmatory data is still expected in Q3 2026. This watch is still active. Let's register some new watches based on the new findings: 1. **EMA decision on Revolution Medicines' daraxonrasib**: Since daraxonrasib entered phased review, we should monitor the outcome of this phased review and the FDA NDA decision. Let's call `record_watch` to track the EMA and FDA regulatory decisions on daraxonrasib. 2. **Presentation of CARDIO-TTRansform full dataset at ESC Congress in late August 2026**: Since AstraZeneca and Ionis announced they will present the full dataset in late August 2026, we should register a watch for this. Let's record the watches.

Now let's record a watch for Revolution Medicines' daraxonrasib regulatory decisions. Since it's a rolling NDA in the US and phased review in the EU, we want to watch for the EMA CHMP opinion or FDA approval decision (expected late 2026 or early 2027). Let's register a watch.

I have written my standing findings, updated the H5N1 bird flu finding, and registered two forward-looking watches based on the events of this cycle. Now, I will call `finish_cycle` to complete this research loop.

I have completed the research cycle for this topic. Here is a summary of the consequential health and science updates uncovered this cycle: ### 1. AstraZeneca & Ionis Suffer Major Phase 3 Blow in Heart Disease AstraZeneca and Ionis Pharmaceuticals announced that their once-monthly subcutaneous RNA-silencing therapy, **Wainua (eplontersen)**, failed to meet its primary objective in the Phase 3 **CARDIO-TTRansform** trial for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The trial, which randomized 1,432 participants, was heavily confounded by standard-of-care stabilizer therapies (with over 80% of patients receiving a stabilizer at some point). In patients on stabilizer therapy at baseline, no treatment effect was observed. This late-stage failure shuts Wainua out of a massive heart disease market and serves as a major competitive boost for Alnylam's Amvuttra (vutrisiran) and BridgeBio's acoramidis. * For more details, see the new finding: `[[eplontersen-wainua-cardio-ttransform-trial]]` * A dated catalyst watch has been registered for the presentation of the full dataset at the ESC Congress in late August 2026. ### 2. Revolution Medicines’ Daraxonrasib Enters Accelerated Phased Review in Europe On July 7, 2026, the European Medicines Agency's (EMA) CHMP initiated a **phased review**—an expedited model under reformed EU pharma rules—for **daraxonrasib (RMC-6236)**, an oral multi-selective RAS(ON) inhibitor for metastatic pancreatic cancer. Concurrently, Revolution Medicines is completing its rolling NDA submission to the U.S. FDA under the Commissioner's National Priority Voucher pilot program. This regulatory momentum is supported by the Phase 3 **RASolute 302** trial, where daraxonrasib nearly **doubled median overall survival to 13.2 months** (vs 6.7 months for cytotoxic chemotherapy; HR 0.40, *P* < 0.0001) with a manageable safety profile and significant quality-of-life benefits. * For more details, see the new finding: `[[revolution-medicines-daraxonrasib-pancreatic-cancer]]` * A live process watch has been registered to track upcoming FDA and EMA regulatory decisions. ### 3. Kailera & Hengrui's Oral GLP-1 Candidate HRS-7535 Hits Phase 3 Efficacy but Sparks GI Tolerability Concerns Kailera Therapeutics and Jiangsu Hengrui Pharmaceuticals announced positive topline Phase 3 data in China for their oral small-molecule GLP-1 receptor agonist, **HRS-7535**, in obesity and diabetes. In the 44-week HARBOR-1 obesity trial, the highest daily dose (180 mg) achieved a mean weight loss of **10.9%** (efficacy estimand), which is numerically competitive with next-generation oral pipelines (such as Lilly's Foundayo). However, the clinical data sparked serious concerns due to severe gastrointestinal side effects, with **70% of recipients experiencing nausea and 67% to 69% reporting vomiting**. There were no signs of liver toxicity. Kailera is adjusting its strategy in an ongoing global Phase 2 trial by testing lower starting doses and nighttime cohorts. * For more details, see the new finding: `[[kailera-obesity-pipeline-hrs-7535]]` ### 4. Australia’s H5N1 Bird Flu Outbreak Rises to Eight Confirmed Cases As of July 9, 2026, Australia's confirmed H5N1 cases have risen to **eight** migratory seabirds across Western Australia (5), South Australia (2), and New South Wales (1). The latest SA case was confirmed on July 8 on the Yorke Peninsula. Reassuringly, a massive coastal surveillance survey covering over **5,000 kilometers** of South Australian coastline and 30,000 seabirds/seals found **no evidence of widespread wildlife mortality**. No cases have been detected in commercial poultry or native land birds, though biosecurity warnings are escalating. * For more details, see the updated finding: `[[australia-h5n1-avian-influenza-seabirds]]` (formerly updated July 8, revised in place to include the Yorke Peninsula case and SA survey data).